



DOCKET NO: 220316US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
STEPHEN ARKINSTALL, ET AL. : EXAMINER: CHANG  
SERIAL NO: 10/088,090 :  
FILED: JUNE 21, 2002 : GROUP ART UNIT: 1625  
FOR: PHARMACEUTICALLY ACTIVE :  
SULFONYL AMINO ACID  
DERIVATIVES

SUPPLEMENTAL APPEAL BRIEF SUBMISSION

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

In view of the order of February 3, 2006, Appellants submit a supplemental Appeal Brief containing the Appendix required by 37 CFR & 41.37(c), which had previously been transmitted to the Board (see attached facsimile of January 26, 2006 to Leslie Gordon). The supplemental brief also removes reference to data from pages 37 and 39 in the specification for the reasons explained in Appellants Reply Brief.

Further consideration on the merits is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Daniel J. Pereira, Ph.D.  
Registration No. 45,518


Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)



Docket No.: 220316US0PCT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RE: Application Serial No.: 10/088,090  
Applicants: Stephen ARKINSTALL, et al.  
Filing Date: June 21, 2002  
For: PHARMACEUTICALLY ACTIVE SULFONYL  
AMINO ACID DERIVATIVES  
Group Art Unit: 1625  
Examiner: Chang

SIR:


Attached hereto for filing are the following papers:

- PTO Communication - Return Copy
- Copy of Facsimile to Leslie Gordon at the Board of Appeals w copy/ of Confirmation Receipt dated January 26, 2006
- Supplemental Appeal Brief Submission
- Supplemental Appeal Brief

Our check in the amount of \_\_\_\_\_ is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

  
\_\_\_\_\_  
Daniel J. Pereira, Ph.D.  
Registration No. 45,518

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)



DOCKET NO: 220316US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
STEPHEN ARKINSTALL, ET AL. : EXAMINER: CHANG, CELIA C.  
SERIAL NO: 10/088,090 :  
FILED: JUNE 21, 2002 : GROUP ART UNIT: 1625  
FOR: PHARMACEUTICALLY ACTIVE :  
SULFONYL AMINO ACID  
DERIVATIVES

**SUPPLEMENTAL APPEAL BRIEF**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

This brief is submitted in response to the rejections dated December 29, 2004.

**REAL PARTY OF INTEREST**

The real party of interest herein is Applied Research Systems ARS Holding N.V.,  
Curacao, Netherland Antilles.



### **RELATED APPEALS AND INTERFERENCES**

To the best of Appellants' knowledge, there are no other appeals or interferences which will directly affect or be directly affected by, or have a bearing on, the Board's decision in this appeal.

### **STATUS OF CLAIMS**

Claims 1, 7-9, 17-19, 29-35, 38, 39 and 41-45 are active in this application.

### **STATUS OF AMENDMENTS**

There are no outstanding amendments in this case.

### **SUMMARY OF CLAIMED SUBJECT MATTER**

As described in the specification on page 5:

[I]t is an objective of the present invention to provide relatively small molecules that avoid essentially all of the above-mentioned drawbacks arising from the use of peptides or proteins, however, which are suitable for the treatment of a variety of diseases, in particular of neuronal or the autoimmune system related disorders. It is notably an objective of the present invention to provide relatively small molecule chemical compounds which are able to modulate, preferably down-regulate or to inhibit the JNK (Jun Kinase) pathway so to be available as a convenient method of treating diseases which are preferably mediated by the JNK function.

Further, on page 9 of the specification describes:

Quite surprisingly, it was now found that sulfonyl amino acid derivatives according to formula I are suitable pharmaceutically active agents, by effectively inhibiting the action of JNKs, notably JNK2 and 3. In terms of application convenience, the inventively found compounds display marked superiority compared to the above mentioned peptide or protein approach as they are also accessible to oral administration. They could

be prescribed by a physician and require only minor supervision. Also, the inventively found compounds are available at lower costs compared to said peptide compounds described hitherto.

On page 13, line 24 – page 14, line 3 the specification describes:

...the compounds pursuant to formula I are useful for the treatment or prevention of immuno- and/or neuronal-related diseases or pathological states in which inhibition of JNK1 and/or JNK2 and/or JNK3 plays a critical role such as epilepsy; neurodegenerative diseases including Alzheimer's disease, Huntington's disease, Parkinson's disease; retinal diseases; spinal cord injury; head trauma, autoimmune diseases including multiple Sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis; asthma; septic shock; transplant rejection; cancers including breast, colorectal, pancreatic and cardiovascular diseases including stroke, cerebral ischemia, arterosclerosis, myocordial infarction, myocordial reperfusion injury.

**ISSUES TO BE REVIEWED ON APPEAL**

- (1) The first issue to be reviewed on appeal is the rejection Claims 1, 7-8, 17-19, 29-35, and 38-39 under 35 U.S.C. § 112, first paragraph based on the allegation that the claims include new matter.
- (2) The issue issued to be reviewed on appeal is the objection of Claims 9 and 29 under 37 CFR 1.75(c) based on the allegation that Claims 9 and 29 fail to further limit the claims from which they depend.
- (3) The third issue to be reviewed on appeal is the rejection of Claims 1, 7-8, 17-19, 29-35, 38-39 and 41-45 under 35 U.S.C. § 112 first paragraph based on the allegation that the claims fail to comply with the written description and enablement requirements.
- (4) The fourth and final issue to be reviewed on appeal is the rejection of Claim 1 under 35 U.S.C. § 103(a) in view of U.S. patent no. 6,646,149.

## ARGUMENT

### Issue #1

This rejection should be reversed for the simple reason that contrary to the position taken by the Office up to this point, the specification provides explicit, literal support for the definitions of the substituents set forth in Claim 1.

In maintaining this rejection, the Office contends that : “the scope of the generic concept to R3 and R4 are both hydrogen together with the subcombination of Markush elements as now recited in the “currently amended” claim 1 is NEW MATTER.” (page 2 of the Office Action mailed December 29, 2004). This conclusion is incorrect because support for Claim 1 finds explicit, literal support on page 11, lines 10-25 reproduced below (emphases added):

In preferred sulfonyl amino acid derivatives according to formula I, Ar<sup>1</sup> is an unsubstituted or substituted phenyl, preferably a 4-chlorophenyl group, X is preferably O, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are preferably hydrogen, n is 1, Ar<sup>2</sup> is preferably thienyl, R<sup>5</sup> is H or C<sub>1</sub>-C<sub>6</sub>-alkyl.

In said preferred embodiment, R<sup>6</sup> is selected from the group comprising or consisting of H, a substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-aliphatic alkyl-e.g. a C<sub>1</sub>-C<sub>6</sub>-alkylamino aryl, a C<sub>1</sub>-C<sub>6</sub>-alkylamino heteroaryl, a substituted or unsubstituted cyclic C<sub>4</sub>-C<sub>8</sub>-alkyl containing optionally 1-3 heteroatoms and being optionally fused with an unsubstituted or substituted aryl or heteroaryl; or R<sup>6</sup> is an unsubstituted or substituted aryl or heteroaryl.

The above mentioned aryl or heteroaryl groups are optionally substituted by substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, like trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxyl, nitro, acyloxy, sulfoxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-thioalkoxy.

For ease of reference, below is a Table which aligns the substituents set forth in Claim 1 and the above-noted portions of the specification supporting each of these substituents:

CLAIM 1 SUBSTITUENTS	SUPPORTING DISCLOSURE ON PAGE 10
<i>Ar<sup>1</sup> is unsubstituted phenyl or phenyl substituted with one or more substituents selected from the group consisting of . . .</i>	Ar <sup>1</sup> is an unsubstituted or substituted phenyl
<i>Ar<sup>2</sup> is thienyl;</i>	"Ar <sup>2</sup> is preferably thienyl"
<i>X is O;</i>	"X is preferably O"
<i>n is 1;</i>	"n is 1"
<i>R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are hydrogen;</i>	"R <sup>1</sup> , R <sup>2</sup> , R <sup>3</sup> and R <sup>4</sup> are preferably hydrogen"
<i>R<sup>5</sup> is H or C<sub>1</sub>-C<sub>6</sub>-alkyl;</i>	"R <sup>5</sup> is H or C <sub>1</sub> -C <sub>6</sub> -alkyl"
<i>R<sup>6</sup> is selected from the group consisting of H, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-aliphatic alkyl, and substituted or unsubstituted saturated cyclic C<sub>4</sub>-C<sub>8</sub>-alkyl optionally containing 1-3 heteroatoms and optionally fused with an unsubstituted or substituted aryl or an heteroaryl; or R<sup>6</sup> is a substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl,</i>	"R <sup>6</sup> is selected from the group comprising or consisting of H, a substituted or unsubstituted C <sub>1</sub> -C <sub>6</sub> -aliphatic alkyl-e.g. a C <sub>1</sub> -C <sub>6</sub> -alkylamino aryl, a C <sub>1</sub> -C <sub>6</sub> -alkylamino heteroaryl, a substituted or unsubstituted cyclic C <sub>4</sub> -C <sub>8</sub> -alkyl containing optionally 1-3 heteroatoms and being optionally fused with an unsubstituted or substituted aryl or heteroaryl; or R <sup>6</sup> is an unsubstituted or substituted aryl or heteroaryl"
<i>wherein said aryl or heteroaryl groups may be substituted with one or more substituents selected from the group consisting of substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, acyloxy, acylamino, sulfoxy, sulfonyl, and C<sub>1</sub>-C<sub>6</sub>-thioalkoxy.</i>	"The above mentioned aryl or heteroaryl groups are optionally substituted by substituted or unsubstituted C <sub>1</sub> -C <sub>6</sub> -alkyl, like trihalomethyl, substituted or unsubstituted C <sub>1</sub> -C <sub>6</sub> -alkoxy, substituted or unsubstituted C <sub>2</sub> -C <sub>6</sub> -alkenyl, substituted or unsubstituted C <sub>2</sub> -C <sub>6</sub> -alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C <sub>1</sub> -C <sub>6</sub> -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxyl, nitro, acyloxy, sulfoxy, sulfonyl, C <sub>1</sub> -C <sub>6</sub> -thioalkoxy."

In view of this explicit, literal support why has this rejection even been raised? It seems that, perhaps, the Office's confusion of this point lies in the disclosure of one embodiment of the compounds of formula 1 on page 10. Illustrative of this is the Office's statements on page 2 of the Office Action of December 29, 2004 pointing to the present



specification on page 10, which states that in one embodiment of the compounds of formula spanning pages 9-10: “at least one of R<sup>3</sup> and/or R<sup>4</sup> must be an amino acid residue.” (see also the Office Action mailed December 29, 2004 at page 2).

However, the Office’s reliance on the disclosure on page 10 stating that R<sup>3</sup> and/ R<sup>4</sup> must be an amino acid residue is misplaced. What the Office has failed to appreciate is that the description of R<sup>3</sup> and R<sup>4</sup> is only one embodiment of the compounds of the formula (1), while the compounds defined as a preferred embodiment on page 11 (reproduced above), is another embodiment. In fact, by simply reviewing the disclosure on pages 9 through 12 one can appreciate that there are several embodiments.

Furthermore, there are specific examples provided in the specification that clearly demonstrate that the specification describes compounds within this generic disclosure on page 11. Examples 1, 4 and 6 describe species within the generic disclosure claimed and described hereinabove.

Therefore, the specification clearly provides **explicit, literal support** for the generic formula defined in Claim 1 as one preferred embodiment, which may overlap and/or be separate from other embodiments described in the specification, including those described on pages 9-10.

As this rejection applies to Claim 9 (see page 3 of the Office Action mailed December 29, 2004), the rejection is without merit. When discussing Claim 9 and Claim 1, the Office has stated that “all compounds of claim 9 have an R<sup>6</sup> being alkyl substituted with “heteroaryl-amino” moiety. . . The instantly amended claim 1 is drawn to R<sup>6</sup> being substituted C<sub>1</sub>-C<sub>6</sub> aliphatic alkyl.” This is simply incorrect.

Claim 1 defines R<sup>6</sup> as follows (see Appendix I):

R<sup>6</sup> is selected from the group consisting of

H, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-aliphatic alkyl, and substituted or unsubstituted saturated cyclic C<sub>4</sub>-C<sub>8</sub>-alkyl optionally containing 1-3 heteroatoms and optionally fused with an unsubstituted or substituted aryl or an heteroaryl; or R<sup>6</sup> is a substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl . . .

The claims clearly include other possible substituents at the R<sup>6</sup> position other than C<sub>1-6</sub> aliphatic alkyl. The Office purports that the groups available as substituents for the the R<sup>6</sup> position are limited to those listed in the paragraph bridging pages 11-12 of the specification (see Page 3 of the Office Action of December 29, 2004). However, what the Office has failed to appreciate is that this disclosure relates to a subset of embodiments within the general formula I. Alternative embodiments are also disclosed falling within the chosen substituents for the R<sup>6</sup> position. In fact, attention is directed to page 7, line 24 to page 8, line 10, reproduced below for reference:

"Substituted or unsubstituted" : Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like alkyl, heteroaryl, alkenyl, alkynyl and aryl etc. groups can optionally be substituted with from 1 to 5 substituents selected from group consisting of C1-C6-alkyl, acetoxy, alkoxy, alkenyl, alkynyl, amino, aminoacyl, aminocarbonyl, alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, sulfoxy, thioalkoxy, trihalomethyl and the like.

Thus, it is readily apparent that the rejection as it applies to Claim 9 (and Claim 29, see below) is based on several mistakes. First, the R<sup>6</sup> position is not limited to only substituted C<sub>1-6</sub> aliphatic alkyl. Second, the possible substituents available at the R<sup>6</sup> position are not limited solely to the one preferred set of embodiments listed on pages 10-11 because the specification provides additional disclosure. Taken together, support for the species listed in Claim 9 (as well as Claim 29) is found in the specification and find proper antecedent basis in the Claim 1.

There is no question that in view of the above facts, this ground of rejection should be REVERSED.

Issue #2

This issue is an objection under 37 C.F.R. 1.75(c) and is based on the allegation “that the base claim 1 as now amended, reading in light of the specification, does not contain the R<sub>6</sub> moieties as found in claim 9, thus, claim 9 is broadening of the base claim.” (See page 3 of the Office Action mailed December 29, 2004). Since no further details are provided by the Office, it is difficult to understand the basis for this rejection. Nonetheless, as readily apparent by the comments below, Claims 9 and 29 are properly dependent from Claim 1.

This objection stems from the misunderstanding of what is claimed, i.e., the R<sub>6</sub> substituents. As discussed in detail above, the compounds in Claim 9 and Claim 29 further define the substituents in the compound of formula I. In fact, the R<sub>6</sub> substituents listed in Claim 1 when properly read, i.e., not limited to some of the examples in the specification, encompass the specific R<sub>6</sub> substituent defined by the compounds set forth in Claims 9 and 29 and therefore further limit Claim 1.

Accordingly, this objection should be REVERSED.

ISSUE # 3

This issue relates to the Office's contention that the specification fails to comply with the written description and enablement requirements. However, as written description is separate and apart from enablement, in the comments below Appellants will explain why all of the pending claims satisfy both of these requirements, addressing each requirement separately.

There are four types of claims in this application: (1) the compound—Claims 1, 7, 8, 9, 29, 39, and 41; (2) processes for preparing the compound—Claims 18 and 19; (3) a composition comprising at least one of the compounds—Claim 17; and (4) methods of using the compounds—Claims 30-38 and 42-45.

For the reasons explained above, the specification unequivocally describes the compounds of formula I (again referring to the text at page 11). The pharmaceutical composition of Claim 17 is described starting on page 12, line 24. Therefore, as this rejection is applied on written description grounds to Claims 1, 7, 8, 9, 17, 29, 39 and 41, the rejection should be reversed.

To the issue of enablement of these claims, i.e., how to make and how to use, the specification at page 13, line 24 – page 14, line 3 describes how the compounds can be used:

...the compounds pursuant to formula I are useful for the treatment or prevention of immuno- and/or neuronal-related diseases or pathological states in which inhibition of JNK1 and/or JNK2 and/or JNK3 plays a critical role such as epilepsy; neurodegenerative diseases including Alzheimer's disease, Huntington's disease, Parkinson's disease; retinal diseases; spinal cord injury; head trauma, autoimmune diseases including multiple Sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis; asthma; septic shock; transplant rejection; cancers including breast, colorectal, pancreatic and cardiovascular diseases including stroke, cerebral ischemia, arterosclerosis, myocardial infarction, myocardial reperfusion injury.

Starting on page 15, line 17, the specification describes how to make the compounds of formula I. On page 16, starting at line 1 a detailed preferred method of synthesis is also described. In addition, on pages 26-30, several detailed examples of making compounds of formula I are described. Therefore, the compound claims as well as the pharmaceutical composition containing the same are clearly enabled by the specification.

Furthermore, in light of the fact that the specification on pages 15 and 17 describes the process steps of making compounds of formula I, the methods for preparing the compounds as set forth in Claims 18 and 19 are clearly adequately described by the specification. Still further, in light of the fact that the Applicants have demonstrated that these processes can be used to make compounds within the definition of formula I in the Examples and the Office has not provided any evidence or rationale as to why one would expect these processes not to work, the processes claimed in Claims 18 and 19 are also enabled.

Turning to the methods of using the compounds to (a) treat a disease of the autoimmune and/or neuronal system (e.g., Claim 30), (b) treat cancer (Claim 42), and (c) treat a cardiovascular disease, Appellants submit that the claims are both adequately described and enabled by the specification as originally filed. There are a number of issues raised by the Office in rejecting these claims (page 4 of the Office Action of December 29, 2004): (1) “down regulate or inhibit” allegedly is new matter; and (2) “the method of using the compounds for such an array of enormous utility in treating all autoimmune disease and/or neuronal system is incredible” and “the claims of treating such disorder of the autoimmune and/or neuronal system constitutes ‘reach through claims.’” Each of these is discussed separately below.

Claim 33 includes the phrase “to down-regulate or inhibit the JNK pathway.” Attention is directed to the specification at page 5, lines 6-10, which states (emphasis added):

It is notably an objective of the present invention to provide relatively small molecule chemical compounds which are able to modulate, preferably **down-regulate or to inhibit the JNK (Jun Kinase) pathway** so to be available as a convenient method of treating diseases which are preferably mediated by the JNK function.

So how is there no antecedent basis for the phrase found in Claim 33? Clearly, the addition of this phrase into Claim 33 does not constitute new matter as the Office has alleged. Furthermore, the specification on pages 37, 38 and 39 describe *in vivo* test data in mice and gerbils. The resultant observations when tied back to the description of how JNK is involved in these diseases clearly provides a nexus for the phrase found in the claims.

The method of using the compounds to treat a disorder of the autoimmune and/or neuronal system is both described and enabled by the specification.

Attention is directed to the following statements in the specification (emphases added):

Page 13, line 24 – page 14, line 3: Specifically, **the compounds pursuant to formula I are useful for the treatment or prevention of immuno- and/or neuronal-related diseases or pathological states in which inhibition of JNK1 and/or JNK2 and/or JNK3 plays a critical role** such as epilepsy; neurodegenerative diseases including Alzheimer's disease, Huntington's disease, Parkinson's disease; retinal diseases; spinal cord injury; head trauma, autoimmune diseases including multiple Sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis; asthma; septic shock; transplant rejection; **cancers including breast, colorectal, pancreatic and cardiovascular diseases including stroke, cerebral ischemia, arterosclerosis, myocordial infarction, myocordial reperfusion injury.**

Here, the specification establishes that the compounds of formula I inhibit JNK and since JNK plays a critical role in a variety of autoimmune and/or neuronal system, one would reasonably conclude that that the compounds can be used to treat a variety of disorders. On page 13, line 3 through page 14, line 14, the specification further elaborates on this point:

The compounds according to formula I, alone or in the form of a pharmaceutical composition, are useful for the modulation of the JNK pathway, more specifically for treatment or prevention

of disorders associated with abnormal expression or activity of JNK, notably of JNK1 and/or JNK2 and/or JNK3. . .

Specifically, the compounds pursuant to formula I are useful for the treatment or prevention of immuno- and/or neuronal-related diseases or pathological states in which inhibition of JNK1 and/or JNK2 and/or JNK3 plays a critical role such as . .

Quite surprisingly, it was now found that sulfonyl amino acid derivatives according to formula I are suitable pharmaceutically active agents, by effectively inhibiting the action of JNKs, notably JNK2 and 3. . .

However, the specification does more than state conclusions. The specification provides clear evidence of the activities of the compounds of formula I. Provided with the nexus discussed above and described in the specification, one of ordinary skill in the art would recognize that the Inventors had possession of the claimed methods. Furthermore, one of ordinary skill in the art could make and/or use the invention as claimed. Specifically, attention is directed to both the *in vitro* and *in vivo* data presented in the specification on pages 32 and 34, portions of which are highlighted and reproduced below for easy reference:

Page 32, lines 6-17: The activities of the sulfonyl amino acid derivatives according to formula I were assessed using the above described biological assays. Representative values are given in the table shown below:

<i>Example</i>	<i>JNK3</i>	<i>JNK2</i>	<i>p38</i>	<i>ERK2</i>
<b>1</b>	1.2	2.7	>30	>30
<b>6</b>	0.64	1.3	>30	>30

The values indicated in respect of JNK2 and 3, p38 and ERK2 refer to the IC<sub>50</sub> (μM), i.e. the amount necessary to **achieve 50% inhibition of said target (e.g. JNK2)**. AS# denotes an exemplary test compound as set out with its number in the above examples. From the above table it could be derived that said test compounds according to formula I do have a significant effect both on JNK2 and 3, but virtually no effect onto p38 and ERK2, thus delivering a **quite selective inhibitory effect**.

Page 34, lines 26-27 (emphasis added): “The result of this assay shows that various test compounds **decrease the production of IL-2 of more than 30% @ 3uM.**”

As described in the specification on pages 1-4, JNK (Jun kinase) act by its central involvement in crucial signaling pathways in the cell and as a result is integral to a number of pathways centered on expression genes, maintaining cell viability, and mediating signals from cytokines such as interleukin 2 and interferon. Furthermore, the specification describes that these activities are involved in a number of diseases and therefore by controlling the activity of JNKs one has the tool to treat these different disease states. Other than simply stating conclusions that the claims are “incredible”<sup>1</sup> or “reach through claims”<sup>2</sup> the Office has not provided any evidence or any reasonable basis to contradict what is so well explained in the specification and known by the skilled artisan.

Accordingly and in view of the above, this rejection should be reversed.

---

<sup>1</sup> Page 4 of the Office Action mailed December 29, 2004.

<sup>2</sup> Page 4 of the Office Action mailed December 29, 2004.



ISSUE #4

Claim 1 is patentable in view of U.S. patent no. 6,646,149 (“U.S. ‘149”) because the generic disclosure of U.S. ‘149 does not provide any reasonable suggestion for the compounds claimed in Claim 1, the disclosure actually found in U.S. ‘149 is inapplicable to the compound claimed in Claim 1, and nothing the Office has proffered counters the surprising advantages the specification has described. Further details on these three points follows.


U.S. ‘149 describes bispolyamines having the general formula set forth in col. 15, lines 40-43. The U.S. ‘149 specification then goes on to list a laundry list of possible substituents the combinations of which appear to encompass thousands of possible compounds. The Office, citing compounds 1233 and 1241 on sheet 29 of the drawings of U.S. ‘149 then contends that “the instant claim is merely picking and choosing of a more limited combination of the generically disclosures alternatives by Vermeulin et al. ‘149.” (page 5 of the Office Action). Appellants respectfully disagree.

First, the enormous possible number of combinations encompassed by U.S. ‘149 provides no reasonable suggestion for the compounds as claimed in Claim 1. On this basis alone, the rejection should be REVERSED.

Second, the compounds claimed in Claim 1 and those described in U.S. ‘149 are fundamentally different. The compounds of U.S. ‘149 as described in col. 15, lines 31-34 are **polyamine derivatives that are linked together via terminal amino groups** . . . In fact, the compounds cited by the Office for alleged support for the rejection also include polyamine moieties. For ease of reference, attached as evidence and listed in Appendix II is Sheet 29 of 59, Figure 9B(6) of U.S. ‘149.

In contrast, the compounds defined by formula I do not contain polyamine groups. In the formula I found in Claim 1 (reproduced below for easy reference), following the

sulfamide moiety (-SO<sub>2</sub>-N-), there is a CH<sub>2</sub> group (noting that R<sub>3</sub> and R<sub>4</sub> are both defined as hydrogen:



On this basis alone and in combination with the above, this rejection should be REVERSED.

Third, as explained in the section of this Brief entitled “Summary of Claimed Subject Matter” the specification at page 9 states: “Quite surprisingly, it was now found that sulfonyl amino acid derivatives according to formula I are suitable pharmaceutically active agents, by effectively inhibiting the action of JNKs, notably JNK2 and 3.” This statement is supported by data also discussed above and found in the specification at page 32, lines 6-17; page 34, lines 26-27; page 37, lines 11-12; page 37, lines 24-25; and page 39, lines 4-5.

Accordingly, on this basis alone and in combination with the above points, this rejection should be REVERSED.

**CONCLUSION**

In view of the above remarks, Appellants request that all of the rejections be  
REVERSED.

Customer Number

**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 08/03)

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon




---

Daniel J. Pereira, Ph.D.  
Registration No. 45,518

**APPENDIX 1 (CLAIMS)**

Claim 1 (Previously Presented): A compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar<sup>1</sup> is unsubstituted phenyl or phenyl substituted with one or more substituents selected from the group consisting of substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, acyloxy, acylamino, sulfoxy, sulfonyl, and substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>- thioalkoxy;

Ar<sup>2</sup> is thienyl;

X is O;

n is 1;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are hydrogen;

R<sup>5</sup> is H or C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sup>6</sup> is selected from the group consisting of H, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-aliphatic alkyl, and substituted or unsubstituted saturated cyclic C<sub>4</sub>-C<sub>8</sub>-alkyl optionally containing 1-3 heteroatoms and optionally fused with an unsubstituted or substituted aryl or an heteroaryl; or R<sup>6</sup> is a substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl,

wherein said aryl or heteroaryl groups may be substituted with one or more substituents selected from the group consisting of substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, acyloxy, acylamino, sulfoxy, sulfonyl, and C<sub>1</sub>-C<sub>6</sub>-thioalkoxy.

Claims 2-6 (Cancelled).

Claim 7 (Previously Presented): The compound according to claim 1, wherein R<sup>5</sup> is H; and R<sup>6</sup> is a C<sub>1</sub>-C<sub>6</sub>-alkyl which is substituted by one or more substituents selected from the group consisting of an aryl, an heteroaryl group, an aminoaryl, aminoheteroaryl, aryloxy, and heteroaryloxy,

wherein said aryl and heteroaryl groups are optionally substituted by substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, substituted or unsubstituted aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, or C<sub>1</sub>-C<sub>6</sub>-thioalkoxy.

Claim 8 (Previously Presented): The compound according to claim 7, wherein R<sup>6</sup> is a substituted or unsubstituted pyridyl group.

Claim 9 (Previously Presented): A compound according to claim 1 which is:  
4-chloro-N-((5-[(2-[(2-[(3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino)ethyl)-amino]-2-oxoethyl)amino)sulfonyl]thien-2-yl)methyl)benzamide,

4-chloro-N-[(5-[[2-[(2-{5-nitropyridin-2-yl} amino)ethyl]amino}-2-oxoethyl)-amino]sulfonyl]thien-2-yl)methyl]benzamide,

4-chloro-N-({5-[(2-oxo-2-[(2-{3-(trifluoromethyl)pyridin-2-yl}amino)ethyl]-amino]ethyl} amino)sulfonyl]thien-2-yl} methyl)benzamide,

4-chloro-N-({5-[(2-oxo-2-[(2-{5-(trifluoromethyl)pyridin-2-yl}amino)ethyl]-amino]ethyl} amino)sulfonyl]thien-2-yl} methyl)benzamide, or


4-chloro-N-[(5-[(2-oxo-2-{3-[(trifluoromethyl)sulfonyl]anilino}ethyl)amino]-sulfonyl]thien-2-yl)methyl]benzamide.

Claims 10-16 (Cancelled).


Claim 17 (Previously Presented): A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

Claim 18 (Previously Presented): A process for the preparation of the compound according to claim 1 comprising:


- a) preparing a sulfonyl compound V,



- b) reacting the sulfonyl compound V with the a protected amino acid compound VIII




to obtain a compound IX




- c) deprotecting the compound IX and then
- d) coupling with an amine of type  $\text{R}^5\text{R}^4\text{NH}$ .

Claim 19 (Previously Presented): A process for the preparation of the compound according to claim 1, comprising:


- a) preparing a protected sulfonyl compound VII



- b) reacting the sulfonyl compound VII with a protected amino acid compound VIII



to obtain a compound X, then



- e) deprotecting the compound X;
- f) coupling with an amine of type  $\text{R}^5\text{R}^4\text{NH}$ ;
- g) deprotecting, and
- h) acylating.

Claims 20-28 (Cancelled).

Claim 29 (Previously Presented): The compound according to claim 1, which is 4-chloro-N-((5-[(2-[(2-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]-2-oxoethyl]amino)sulfonyl]thien-2-yl)methyl)benzamide.

Claim 30 (Previously Presented): A method to treat a disorder of the autoimmune and/or neuronal system comprising

administering the compound of claim 1 to a mammal in need thereof in an amount effective to treat a disorder of the autoimmune and/or neuronal system.

Claim 31 (Previously Presented): The method according to claim 30, wherein the mammal is a human.

Claim 32 (Previously Presented): The method of claim 30, wherein the compound is administered orally.

Claim 33 (Previously Presented): A method to treat a disorder of the autoimmune and/or neuronal system comprising

administering the compound of claim 1 to a human in an amount effective to down-regulate or inhibit the JNK pathway.

Claim 34 (Previously Presented): The method of claim 30, wherein the compound is administered to a human having at least one neuronal disorder selected from the group



consisting of epilepsy, Alzheimer's disease, Huntington's disease, Parkinson's disease, retinal disease, spinal cord injury, and head trauma.

Claim 35 (Previously Presented): The method of claim 30, wherein the compound is administered to a human having at least one autoimmune disease selected from the group consisting of multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, asthma, septic shock, and transplant rejection.

Claims 36-37 (Canceled).

Claim 38 (Previously Presented): The method of claim 30, wherein the compound is administered in an amount effective for decreasing the production of IL-2.

Claim 39 (Previously Presented): The compound according to claim 1, wherein Ar<sup>1</sup> is a chloro-phenyl group.

Claim 40 (Canceled).

Claim 41 (Previously Presented): The compound according to claim 1, wherein R<sup>6</sup> is a C<sub>1</sub>-C<sub>6</sub>-alkyl which is substituted by substituents selected from the group consisting of an aryl, an heteroaryl group, an aminoaryl, aminoheteroaryl, aryloxy, and heteroaryloxy,

wherein said aryl and heteroaryl groups are optionally substituted by substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, trihalomethyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxy, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl, substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkynyl, amino,

acylamino, aminocarbonyl, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, substituted or unsubstituted aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, or C<sub>1</sub>-C<sub>6</sub>-thioalkoxy.

Claim 42 (Previously Presented): A method to treat cancer comprising administering the compound of claim 1 to a mammal in need thereof in an amount effective to treat cancer.

Claim 43 (Previously Presented): The method of claim 42, wherein the compound is administered to a human having breast cancer, colorectal cancer, or pancreatic cancer.

Claim 44 (Previously Presented): A method to treat cardiovascular disease comprising administering the compound of claim 1 to a mammal in need thereof in an amount effective to treat cardiovascular disease.

Claim 45 (Previously Presented): The method of claim 44, wherein the compound is administered to a human having at least one cardiovascular disease selected from the group consisting of stroke arteriosclerosis, myocardial infarction, and myocardial reperfusion injury.

**APPENDIX II (EVIDENCE)**

1. U.S. patent no.6,646,149, Figure 9(B)-6, Sheet 29 of 59. Entered in the record on December 29, 2004 by citation in the U.S.P.T.O Office Action of the same date.

Application No. 10/088,090  
Appeal Brief

**RELATED PROCEEDINGS APPENDIX**

None.



UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES

2203164569A

MAILED

FEB 03 2006

PAT. & T.M. OFFICE  
BOARD OF PATENT APPEALS  
AND INTERFERENCES

Ex parte STEPHEN ARKINSTALL, SERGE HALAZY, DENNIS CHURCH,  
MONTERRAT CAMPS, THOMAS RUECKLE, JEAN PIERRE GOTTELAND  
and MARCO BIAMONTE

RECEIVED: 2606  
OBLON, SPIVAK, McCLELLAND  
MAIER & NEUSTADT, P.C.

DOCKETING DEPT

Initials/Date Docketed: 076-2606 Application No. 10/088,090  
Type of Resp(s): \_\_\_\_\_  
Due Date(s): \_\_\_\_\_

ORDER RETURNING UNDOCKETED APPEAL TO EXAMINER

This application was received at the Board of Patent Appeals and Interferences on January 10, 2006. A review of the application has revealed that the application is not ready for docketing as an appeal. Accordingly, the application is herewith being returned to the examiner. The matters requiring attention prior to docketing are identified below.

On December 2, 2005, appellants filed a reply brief in response to the Examiner's answer mailed October 3, 2005. However, there is no indication on the record whether or not the

Application No. 10/088,090

examiner has responded to the reply brief. Section § 1208.03 of the Manual of Patent Examining Procedure (8<sup>th</sup> ed., Aug. 2001) states:

[A]ppellant may file a reply brief as a matter of right within 2 months from the mailing date of the examiner's answer. . . . The primary must then either: (A) acknowledge receipt and entry of the reply brief by using form paragraph 12.47 on form PTOL-90; or (B) reopen prosecution to respond to the reply brief. See MPEP § 1208.02 [emphasis added].

Furthermore, the appeal brief filed July 27, 2005, did not fully comply with 37 CFR § 41.37(c).

37 CFR § 41.37(c) states in part:

(x) *Related proceedings appendix*. An appendix containing copies of decisions rendered by a court or the Board in any proceeding identified pursuant to paragraph (c)(1)(ii) of this section.

A review of the application indicates that the following appropriate sections are missing from the appeal brief filed July 27, 2005:

1) "Related proceedings appendix" as set forth in 37 CFR § 41.37(c)(1)(x).

A supplemental appeal brief in compliance with 37 CFR § 41.37 is required. For more information on the Board's new rules see the web page entitled:

<http://www.uspto.gov/web/offices/dcom/bpai/fr2004/moreinfo.html>.

Application No. 10/088,090

Also, the Information Disclosure Statements dated April 4, 2003 and October 8, 2003, were not considered by the Primary Examiner with respect to compliance with the criteria set forth in 37 CFR §§ 1.97 and 1.98. A written communication notifying appellants of the Primary Examiner's decision is required.

Accordingly, it is


**ORDERED** that this application be returned to the examiner to: 1) hold the appeal brief of July 27, 2005 defective; 2) request appellants to file a supplemental appeal brief in compliance with 37 CFR § 41.37 or to submit a statement by the examiner presenting an assumed status regarding the appendix which is missing; 3) for proper response to the reply brief filed December 2, 2005; 4) for consideration of the Information Disclosure Statements; 5) written communication to appellants of such consideration; and 6) for such further action as may be appropriate.

Application No. 10/088,090

It is important that the Board of Patent Appeals and Interferences be informed promptly of any action affecting the status of this appeal (i.e., abandonment, issue, reopening prosecution).

BOARD OF PATENT APPEALS  
AND INTERFERENCES

By: \_\_\_\_\_

  
Craig R. Feinberg  
Program and Resource Administrator  
(571) 272-9797

cc: OBLON, SPIVAK, MCCLELLAND, MAIER  
& NEUSTADT, P.C.  
1940 DUKE STREET  
ALEXANDRIA, VA 22314

CRF/lbg



TTI OBLON, SPIVAK

DATE	TIME	ADDRESS	MODE	TIME	PAGE	RESULT	PERS. NAME	FILE
JAN.26.	3:08PM	+97033086199	TES	0'28"	P. 2	OK		638




COPY

# : BATCH  
M : MEMORY  
S : STANDARD  
\* : PC

C : CONFIDENTIAL  
L : SEND LATER  
D : DETAIL  
% : PC DIRECT

\$ : TRANSFER  
@ : FORWARDING  
F : FINE

P : POLLING  
E : ECM  
> : REDUCTION



COPY

**FACSIMILE**

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

ATTORNEYS AT LAW

1940 DUKE STREET  
ALEXANDRIA, VIRGINIA 22314  
USA

(703) 413-3000  
(703) 413-2220 FACSIMILE

OBLONPAT@OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW  
AND RELATED FEDERAL AND ITC LITIGATION

WWW.OBLON.COM

TO	Leslie Gordon	January 26, 2006
NAME	Board of Patent Appeals and Interferences, USPTO	DATE
COMPANY/FIRM		571-273-0299
NUMBER OF PAGES INCLUDING COVER:	2	FAX #
		CONFIRM FAX: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
FROM	Daniel Pereira	220316US
NAME	703-413-6560	OUR REFERENCE
DIRECT PHONE #		US 10/088,090
		YOUR REFERENCE

**MESSAGE**

Dear Ms. Gordon:

As requested, attached is a related proceedings appendix.

Thank you for your assistance in this matter. If you require anything further, please feel free to call me.

Respectfully Submitted,


Daniel J. Pereira  
Registration No. 45,518

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

U.S. Application serial no. 10/088,090  
Appeal Brief

**RELATED PROCEEDINGS APPENDIX**

None.



COPY

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**